{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:07:13Z","timestamp":1793243233941,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009086","name":"Medical University Sofia","doi-asserted-by":"publisher","award":["7418\/19.11.2021"],"award-info":[{"award-number":["7418\/19.11.2021"]}],"id":[{"id":"10.13039\/100009086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009086","name":"Medical University Sofia","doi-asserted-by":"publisher","award":["160\/14.06.2022"],"award-info":[{"award-number":["160\/14.06.2022"]}],"id":[{"id":"10.13039\/100009086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Graphics and Modelling"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jmgm.2023.108471","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T11:52:27Z","timestamp":1681473147000},"page":"108471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Repurposing of FDA-approved drugs as dual-acting MAO-B and AChE inhibitors against Alzheimer's disease: An in silico and in vitro study"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5885-7213","authenticated-orcid":false,"given":"Emilio","family":"Mateev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kondeva-Burdina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Georgieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zlatkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmgm.2023.108471_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12929-019-0609-7","article-title":"Clinical trials of new drugs for Alzheimer disease","volume":"27","author":"Huang","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jmgm.2023.108471_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900177","article-title":"Emerging therapeutic potentials of dual\u2010acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases","volume":"352","author":"Mathew","year":"2019","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.jmgm.2023.108471_bib3","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1016\/j.ejmech.2011.05.048","article-title":"Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease","volume":"46","author":"Samadi","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jmgm.2023.108471_bib4","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1021\/acschemneuro.1c00394","article-title":"FDA approval of aduhelm paves a new path for Alzheimer's disease","volume":"12","author":"Tanzi","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.jmgm.2023.108471_bib5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41582-021-00540-6","article-title":"The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA","volume":"17","author":"Karlawish","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jmgm.2023.108471_bib6","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/0024-3205(78)90011-5","article-title":"Choline: selective enhancement of serial learning and encoding of low imagery words in man","volume":"22","author":"Sitaram","year":"1978","journal-title":"Life Sci."},{"key":"10.1016\/j.jmgm.2023.108471_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","article-title":"Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline","volume":"148","author":"Raina","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jmgm.2023.108471_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13195-017-0279-1","article-title":"Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with \u03b3-secretase and regulates neuronal amyloid \u03b2-peptide levels","volume":"9","author":"Schedin-Weiss","year":"2017","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.jmgm.2023.108471_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/molecules26010080","article-title":"First synthesis of racemic trans propargylamino-donepezil, a pleiotrope agent able to both inhibit AChE and MAO-B, with potential interest against Alzheimer's disease","volume":"26","author":"Guieu","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jmgm.2023.108471_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jmgm.2023.108471_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101815","article-title":"Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer's disease","volume":"85","author":"Neha","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.jmgm.2023.108471_bib12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s40495-022-00285-w","article-title":"Molecular docking as a potential approach in repurposing drugs against COVID-19: a systematic review and novel pharmacophore models","volume":"8","author":"Fadlalla","year":"2022","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.jmgm.2023.108471_bib13","doi-asserted-by":"crossref","first-page":"98080","DOI":"10.1039\/C6RA21941A","article-title":"In silico drug repositioning for the treatment of Alzheimer's disease using molecular docking and gene expression data","volume":"6","author":"Xie","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jmgm.2023.108471_bib14","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1080\/07391102.2020.1844054","article-title":"Drug repurposing for Alzheimer's disease: in silico and in vitro investigation of FDA-approved drugs as acetylcholinesterase inhibitors","volume":"40","author":"Kumar","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.jmgm.2023.108471_bib15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/03639045.2021.1952216","article-title":"Potential alternatives to current cholinesterase inhibitors: an in silico drug repurposing approach","volume":"47","author":"Kundu","year":"2021","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jmgm.2023.108471_bib16","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.biopha.2018.11.115","article-title":"The exploration of novel Alzheimer's therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches","volume":"109","author":"Hassan","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jmgm.2023.108471_bib17","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/med.21862","article-title":"Haste makes waste: a critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition","volume":"42","author":"Macip","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jmgm.2023.108471_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/j.1747-0285.2005.00327.x","article-title":"Use of an induced fit receptor structure in virtual screening","volume":"67","author":"Sherman","year":"2006","journal-title":"Chemical Biology <html_ent glyph=\"@amp;\" ascii=\" & \"\/> Drug Design"},{"key":"10.1016\/j.jmgm.2023.108471_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10822-022-00456-3","article-title":"Consensus scoring evaluated using the GPCR-Bench dataset: reconsidering the role of MM\/GBSA","volume":"36","author":"Yau","year":"2022","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.jmgm.2023.108471_bib20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10822-021-00389-3","article-title":"Improving virtual screening results with MM\/GBSA and MM\/PBSA rescoring","volume":"35","author":"Sahakyan","year":"2021","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.jmgm.2023.108471_bib21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Madhavi Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.jmgm.2023.108471_bib22","doi-asserted-by":"crossref","first-page":"D1137","DOI":"10.1093\/nar\/gkx1088","article-title":"SuperDRUG2: a one stop resource for approved\/marketed drugs","volume":"46","author":"Siramshetty","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmgm.2023.108471_bib23","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision Glide: docking and scoring incorporating a model of hydrophobic enclosure for Protein\u2212Ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmgm.2023.108471_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.33263\/BRIAC132.159","article-title":"Improved molecular docking of MAO-B inhibitors with Glide","volume":"13","author":"Mateev","year":"2022","journal-title":"Biointerface Res. App. Chem."},{"issue":"6","key":"10.1016\/j.jmgm.2023.108471_bib25","first-page":"1525","article-title":"Benchmarking docking protocols for virtual screenings of novel acetylcholinesterase inhibitors","volume":"84","author":"Mateev","year":"2022","journal-title":"Indian J. Pharmaceut. Sci."},{"key":"10.1016\/j.jmgm.2023.108471_bib26","first-page":"1099","article-title":"Validation through re-docking, cross-docking and ligand enrichment in various well-resoluted mao-b receptors","volume":"13","author":"Mateev","year":"2022","journal-title":"Int. J. Pharmaceut. Sci. Res."},{"key":"10.1016\/j.jmgm.2023.108471_bib27","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1021\/ci500081m","article-title":"Comparative assessment of scoring functions on an updated benchmark: 2. Evaluation methods and general results","volume":"54","author":"Li","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.jmgm.2023.108471_bib28","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1021\/ci300399w","article-title":"Consensus docking: improving the reliability of docking in a virtual screening context","volume":"53","author":"Houston","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.jmgm.2023.108471_bib29","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","article-title":"End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design","volume":"119","author":"Wang","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jmgm.2023.108471_bib30","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.3390\/molecules27238485","article-title":"Silico evaluation and in vitro determination of neuroprotective and MAO-B inhibitory effects of pyrrole-based hydrazones: a therapeutic approach to Parkinson's disease","volume":"27","author":"Kondeva-Burdina","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jmgm.2023.108471_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bioorg.2016.05.002","article-title":"Identification of novel acetylcholinesterase inhibitors: indolopyrazoline derivatives and molecular docking studies","volume":"67","author":"Chigurupati","year":"2016","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.jmgm.2023.108471_bib32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2174\/1573407214666181023114820","article-title":"Consensus docking in drug Discovery","volume":"16","author":"Poli","year":"2020","journal-title":"Curr. Bioact. Compd."},{"key":"10.1016\/j.jmgm.2023.108471_bib33","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/ijms20061375","article-title":"The light and dark sides of virtual screening: what is there to know?","volume":"20","author":"Gimeno","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jmgm.2023.108471_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105070","article-title":"Structural exploration of multifunctional monoamine oxidase B inhibitors as potential drug candidates against Alzheimer's disease","volume":"114","author":"Zhang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.jmgm.2023.108471_bib35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.0954-6820.1969.tb07309.x","article-title":"Bladder tumours induced by chlornaphazine","volume":"185","author":"Thiede","year":"2009","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.jmgm.2023.108471_bib36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The \"retinoic acid syndrome\" in acute promyelocytic leukemia","volume":"117","author":"Frankel","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jmgm.2023.108471_bib37","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1586\/14737140.5.6.957","article-title":"Exisulind in the treatment of prostate cancer","volume":"5","author":"Webster","year":"2005","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.jmgm.2023.108471_bib38","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/030006057800600507","article-title":"A comparative double-blind trial of the new antidepressant Caroxazone and amitriptyline","volume":"6","author":"Cecchini","year":"1978","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.jmgm.2023.108471_bib39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1055\/s-0034-1372612","article-title":"The inhibition of acetylcholinesterase by dantrolene and Ondansetron","volume":"65","author":"N\u2019Da","year":"2014","journal-title":"Drug Res."},{"key":"10.1016\/j.jmgm.2023.108471_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/01480549609002193","article-title":"The effect of Ondansetron on pyridostigmine-induced blood acetylcholinesterase inhibition in the Guinea pig","volume":"19","author":"Capacio","year":"1996","journal-title":"Drug Chem. Toxicol."},{"key":"10.1016\/j.jmgm.2023.108471_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100573","article-title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis","volume":"28","author":"Kanters","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jmgm.2023.108471_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40121-014-0029-7","article-title":"The second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV","volume":"3","author":"Dow","year":"2014","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.jmgm.2023.108471_bib43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14740338.2015.973845","article-title":"Evaluation of dolutegravir safety for the treatment of HIV-1","volume":"14","author":"Keeshin","year":"2014","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.jmgm.2023.108471_bib44","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.jiph.2020.10.015","article-title":"Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: a molecular docking and drug repurposing approach","volume":"13","author":"Indu","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.jmgm.2023.108471_bib45","first-page":"1032","volume":"59","author":"Letendre","year":"2014"},{"key":"10.1016\/j.jmgm.2023.108471_bib46","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4103\/0019-5154.117298","article-title":"A novel agent in the treatment of recurrent aphthous ulcer and Behcet's syndrome","volume":"58","author":"Kudur","year":"2013","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.jmgm.2023.108471_bib47","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.2147\/IJGM.S353098","article-title":"Rebamipide as a potential alternative gastroprotective agent to proton pump inhibitor in elderly chronic nonsteroidal anti-inflammatory drug users without risk factors","volume":"15","author":"Lee","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.jmgm.2023.108471_bib48","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/0002-9343(92)90603-9","article-title":"The safety profile of loracarbef: clinical trials in respiratory, skin, and urinary tract infections","volume":"92","author":"Therasse","year":"1992","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jmgm.2023.108471_bib49","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/0002-9343(92)90602-8","article-title":"Pharmacokinetic profile of loracarbef","volume":"92","author":"DeSante","year":"1992","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jmgm.2023.108471_bib50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis","volume":"22","author":"Sekijima","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.jmgm.2023.108471_bib51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2165\/00003495-198019020-00002","volume":"19","author":"Brogden","year":"1980","journal-title":"Diflunisal. Drugs."},{"key":"10.1016\/j.jmgm.2023.108471_bib52","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.tips.2014.12.001","article-title":"Beware of docking","volume":"36","author":"Chen","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jmgm.2023.108471_bib53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.22159\/ijpps.2021v13i8.41956","article-title":"Database enrichments of MAO-B through ensemble docking","author":"Mateev","year":"2021","journal-title":"Int. J. Pharm. Pharmaceut. Sci."},{"key":"10.1016\/j.jmgm.2023.108471_bib54","first-page":"81","article-title":"Selecting machine-learning scoring functions for structure-based virtual screening","volume":"32\u201333","author":"Ballester","year":"2020","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.jmgm.2023.108471_bib55","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/egh.10.25","article-title":"A gastrointestinal protective drug with pleiotropic activities","volume":"4","author":"Naito","year":"2010","journal-title":"Expet Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jmgm.2023.108471_bib56","doi-asserted-by":"crossref","first-page":"834","DOI":"10.6026\/97320630008834","article-title":"Molecular docking and virtual screening for novel protein tyrosine phosphatase 1B (PTP1B) inhibitors","volume":"8","author":"Rao","year":"2012","journal-title":"Bioinformation"},{"key":"10.1016\/j.jmgm.2023.108471_bib57","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1111\/jcmm.17411","article-title":"A reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome","volume":"26","author":"de Lagran","year":"2022","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.jmgm.2023.108471_bib58","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1021\/bi051847g","article-title":"Functional role of the aromatic cage in human monoamine oxidase B: structures and catalytic properties of Tyr435 mutant proteins","volume":"45","author":"Li","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmgm.2023.108471_bib59","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1080\/07391102.2020.1734483","article-title":"The conformational dynamics of wing gates Ile199 and Phe103 on the binding of dopamine and benzylamine substrates in human monoamine Oxidase B","volume":"39","author":"Dasgupta","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.jmgm.2023.108471_bib60","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1021\/acs.jmedchem.7b00918","article-title":"Coumarin versus chromone monoamine oxidase B inhibitors: quo vadis?","volume":"60","author":"Fonseca","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmgm.2023.108471_bib61","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1080\/07391102.2017.1325405","article-title":"Recognition dynamics of dopamine to human Monoamine oxidase B: role of Leu171\/Gln206 and conserved water molecules in the active site cavity","volume":"36","author":"Dasgupta","year":"2017","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.jmgm.2023.108471_bib62","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/jm500729a","article-title":"Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency","volume":"57","author":"Tzvetkov","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmgm.2023.108471_bib63","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/molecules25030489","article-title":"Design, synthesis, and evaluation of acetylcholinesterase and butyrylcholinesterase dual-target inhibitors against Alzheimer's diseases","volume":"25","author":"Guo","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jmgm.2023.108471_bib64","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cbi.2010.04.017","article-title":"Interactions of pyridinium oximes with acetylcholinesterase","volume":"187","author":"\u0160inko","year":"2010","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.jmgm.2023.108471_bib65","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijbiomac.2019.05.132","article-title":"Effect of Salvia miltiorrhiza on acetylcholinesterase: enzyme kinetics and interaction mechanism merging with molecular docking analysis","volume":"135","author":"Tang","year":"2019","journal-title":"Int. J. Biol. Macromol."}],"container-title":["Journal of Molecular Graphics and Modelling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326323000694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326323000694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:43:34Z","timestamp":1778589814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1093326323000694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":65,"alternative-id":["S1093326323000694"],"URL":"https:\/\/doi.org\/10.1016\/j.jmgm.2023.108471","relation":{},"ISSN":["1093-3263"],"issn-type":[{"value":"1093-3263","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing of FDA-approved drugs as dual-acting MAO-B and AChE inhibitors against Alzheimer's disease: An in silico and in vitro study","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Graphics and Modelling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmgm.2023.108471","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108471"}}